MeSH D028227 - familial amyloid neuropathies
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Akcea Therapeutics | Inotersen | Tegsedi | 2023-03-21 | 2018-10-05 | $17.1 M | Q1/19-Q1/20 |
| Alnylam Pharmaceuticals | Vutrisiran | Amvuttra | 2022-09-15 | $859.194 M | Q4/23-Q3/24 |
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
75%3/4
Phase 3
50%3/6
Approved: 2Overall Success rate: 38%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use